Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 1

Status

Completed 4Recruiting 2Terminated 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Breast 13Tumor-Agnostic 7Lymphoid 3Thoracic 2Genitourinary 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Classical hematology 1CNS 1

Conditions

Neoplasm Metastasis 7Neoplasms 6Adenocarcinoma 1

Interventions

pembrolizumab 34Specimen Handling 26Magnetic Resonance Spectroscopy 26Radiosurgery 25Biopsy 25Gemcitabine 22Nivolumab 21Paclitaxel 18Carboplatin 16Bevacizumab 15Trastuzumab 14Everolimus 12Radiotherapy 11Irinotecan 11trastuzumab deruxtecan 10atezolizumab 10Erlotinib Hydrochloride 10Docetaxel 10Cetuximab 10Capecitabine 10Albumin-Bound Paclitaxel 10130-nm albumin-bound paclitaxel 10Sorafenib 9Ipilimumab 9Cisplatin 9Taxes 8Standard of Care 8Oxaliplatin 8Drug Therapy 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Neoplasm Metastasis × abemaciclib × Tumor-Agnostic × Clear all
NCT04802759 2026-05-11

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Hoffmann-La Roche

Phase 1/2 Recruiting
316 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05933395 2026-01-20

GERTRUDE

Dartmouth-Hitchcock Medical Center

Phase 2 Recruiting
135 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04534283 2024-08-07

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

Indiana University

Phase 2 Terminated
16 enrolled 11 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT05789771 2023-03-31

ATLANT

Blokhin's Russian Cancer Research Center

Completed
136 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02688088 2022-10-18

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

Eli Lilly and Company

Phase 1 Completed
48 enrolled 30 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT02919696 2020-09-25

A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers

Eli Lilly and Company

Phase 1 Completed
26 enrolled 16 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT02117648 2019-01-07

A Study of LY2835219 in Participants With Cancer

Eli Lilly and Company

Phase 1 Completed
26 enrolled 11 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡